These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26861284)

  • 1. Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States.
    Hayashi PH
    Int J Mol Sci; 2016 Feb; 17(2):201. PubMed ID: 26861284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.
    Fontana RJ; Watkins PB; Bonkovsky HL; Chalasani N; Davern T; Serrano J; Rochon J;
    Drug Saf; 2009; 32(1):55-68. PubMed ID: 19132805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causality assessment for suspected DILI during clinical phases of drug development.
    Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causality assessment in drug-induced liver injury.
    Hayashi PH
    Semin Liver Dis; 2009 Nov; 29(4):348-56. PubMed ID: 19826968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN).
    Hayashi PH; Barnhart HX; Fontana RJ; Chalasani N; Davern TJ; Talwalkar JA; Reddy KR; Stolz AA; Hoofnagle JH; Rockey DC
    Liver Int; 2015 May; 35(5):1623-32. PubMed ID: 24661785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
    Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
    Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware.
    Vega M; Verma M; Beswick D; Bey S; Hossack J; Merriman N; Shah A; Navarro V;
    Drug Saf; 2017 Sep; 40(9):783-787. PubMed ID: 28555362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Needles in haystacks.
    Reuben A
    Am J Gastroenterol; 2007 Nov; 102(11):2444-6. PubMed ID: 17958757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
    Teschke R
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causality assessment methods in drug induced liver injury: strengths and weaknesses.
    García-Cortés M; Stephens C; Lucena MI; Fernández-Castañer A; Andrade RJ
    J Hepatol; 2011 Sep; 55(3):683-691. PubMed ID: 21349301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
    Fontana RJ; Seeff LB; Andrade RJ; Björnsson E; Day CP; Serrano J; Hoofnagle JH
    Hepatology; 2010 Aug; 52(2):730-42. PubMed ID: 20564754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of liver biopsy in the diagnosis of drug-induced liver injury.
    Ahmad J; Barnhart HX; Bonacini M; Ghabril M; Hayashi PH; Odin JA; Rockey DC; Rossi S; Serrano J; Tillmann HL; Kleiner DE;
    J Hepatol; 2022 May; 76(5):1070-1078. PubMed ID: 35074471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
    Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case definition and phenotype standardization in drug-induced liver injury.
    Aithal GP; Watkins PB; Andrade RJ; Larrey D; Molokhia M; Takikawa H; Hunt CM; Wilke RA; Avigan M; Kaplowitz N; Bjornsson E; Daly AK
    Clin Pharmacol Ther; 2011 Jun; 89(6):806-15. PubMed ID: 21544079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced liver injury: an overview over the most critical compounds.
    Björnsson ES
    Arch Toxicol; 2015 Mar; 89(3):327-34. PubMed ID: 25618544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of drug-induced liver injury in clinical practice.
    Lucena MI; García-Cortés M; Cueto R; Lopez-Duran J; Andrade RJ
    Fundam Clin Pharmacol; 2008 Apr; 22(2):141-58. PubMed ID: 18353109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting.
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):317-22. PubMed ID: 2272712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and causality assessment in herbal hepatotoxicity.
    Teschke R; Schwarzenboeck A; Eickhoff A; Frenzel C; Wolff A; Schulze J
    Expert Opin Drug Saf; 2013 May; 12(3):339-66. PubMed ID: 23458441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human drug hepatotoxicity: a contemporary clinical perspective.
    Assis DN; Navarro VJ
    Expert Opin Drug Metab Toxicol; 2009 May; 5(5):463-73. PubMed ID: 19416083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.
    Björnsson ES; Bergmann OM; Björnsson HK; Kvaran RB; Olafsson S
    Gastroenterology; 2013 Jun; 144(7):1419-25, 1425.e1-3; quiz e19-20. PubMed ID: 23419359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.